Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
20
CCEL Quote, Financials, Valuation and Earnings
Last price:
$3.27
Seasonality move
:
3.6%
Day range:
$3.34 - $3.39
52-week range:
$3.10 - $8.19
Dividend yield:
19.37%
P/E ratio:
498.00x
P/S ratio:
0.86x
P/B ratio:
--
Volume:
5.2K
Avg. volume:
13.9K
1-year change:
-58.32%
Market cap:
$27M
Revenue:
$32M
EPS (TTM):
-$0.06
Analysts' Opinion
-
Consensus RatingCryo-Cell International, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.50, Cryo-Cell International, Inc. has an estimated upside of 153.35% from its current price of $3.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.50 representing 100% downside risk from its current price of $3.36.
Fair Value
-
According to the consensus of 1 analyst, Cryo-Cell International, Inc. has 153.35% upside to fair value with a price target of $8.50 per share.
CCEL vs. S&P 500
-
Over the past 5 trading days, Cryo-Cell International, Inc. has underperformed the S&P 500 by -1.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cryo-Cell International, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cryo-Cell International, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cryo-Cell International, Inc. reported revenues of $7.8M.
Earnings Growth
-
Cryo-Cell International, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Cryo-Cell International, Inc. reported earnings per share of $0.09.
Enterprise value:
36.4M
EV / Invested capital:
--
Price / LTM sales:
0.86x
EV / EBIT:
8.42x
EV / Revenue:
1.15x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.89x
Price / Operating cash flow:
4.41x
Enterprise value / EBITDA:
6.38x
Gross Profit (TTM):
$23.7M
Return On Assets:
-0.74%
Net Income Margin (TTM):
-1.49%
Return On Equity:
--
Return On Invested Capital:
-20.01%
Operating Margin:
24.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Income Statement | ||||||
| Revenue | $31.2M | $31.8M | $31.7M | $8.1M | $7.8M | |
| Gross Profit | $21.6M | $22.9M | $23.7M | $5.7M | $5.8M | |
| Operating Income | $4.4M | -$139.4K | $4.3M | $1.4M | $1.9M | |
| EBITDA | $6.1M | $952.6K | $5.7M | $1.7M | $2.3M | |
| Diluted EPS | $0.30 | -$1.08 | -$0.06 | $0.13 | $0.09 | |
| Period Ending | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.9M | $11.1M | $9.9M | $10.7M | $11.7M | |
| Total Assets | $59.4M | $66.8M | $69.8M | $62.9M | $63.2M | |
| Current Liabilities | $19.9M | $23.6M | $18.6M | $17.4M | $18.5M | |
| Total Liabilities | $54.6M | $69.2M | $69.8M | $72.5M | $78M | |
| Total Equity | $4.8M | -$2.4M | -$16.2K | -$9.6M | -$14.8M | |
| Total Debt | $3.4M | $9.1M | $9.5M | $9.1M | $9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-08-31 | 2024-08-31 | 2025-08-31 | 2024-08-31 | 2025-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $8M | $7.2M | $6.4M | $2.4M | $2.5M | |
| Cash From Investing | -$4.2M | -$5.7M | -$1.8M | -$665.6K | $1.1M | |
| Cash From Financing | -$6.1M | -$1.8M | -$4.5M | -$2M | -$3.5M | |
| Free Cash Flow | $7.4M | $3.1M | $6.2M | $2.3M | $2.5M | |
CCEL
Sector
Market Cap
$27M
$25.5M
Price % of 52-Week High
40.96%
49.47%
Dividend Yield
19.37%
0%
Shareholder Yield
0.78%
-1.77%
1-Year Price Total Return
-58.32%
-21.96%
Beta (5-Year)
0.701
0.499
Dividend yield:
19.37%
Annualized payout:
$0.25
Payout ratio:
3067.58%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.37
200-day SMA
Sell
Level
$4.39
Bollinger Bands (100)
Sell
Level
3.45 - 4.37
Chaikin Money Flow
Buy
Level
3.5M
20-day SMA
Sell
Level
$3.38
Relative Strength Index (RSI14)
Sell
Level
44.04
ADX Line
Buy
Level
7.25
Williams %R
Neutral
Level
-47.2665
50-day SMA
Sell
Level
$3.52
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.3504)
Sell
CA Score
(Annual)
Level (-3.1744)
Buy
Beneish M-Score
(Annual)
Level (-2.7553)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-6.6063)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.
Stock Forecast FAQ
In the current month, CCEL has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CCEL average analyst price target in the past 3 months is $8.50.
-
Where Will Cryo-Cell International, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cryo-Cell International, Inc. share price will rise to $8.50 per share over the next 12 months.
-
What Do Analysts Say About Cryo-Cell International, Inc.?
Analysts are divided on their view about Cryo-Cell International, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cryo-Cell International, Inc. is a Sell and believe this share price will drop from its current level to $8.50.
-
What Is Cryo-Cell International, Inc.'s Price Target?
The price target for Cryo-Cell International, Inc. over the next 1-year time period is forecast to be $8.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CCEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cryo-Cell International, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of CCEL?
You can purchase shares of Cryo-Cell International, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cryo-Cell International, Inc. shares.
-
What Is The Cryo-Cell International, Inc. Share Price Today?
Cryo-Cell International, Inc. was last trading at $3.27 per share. This represents the most recent stock quote for Cryo-Cell International, Inc.. Yesterday, Cryo-Cell International, Inc. closed at $3.36 per share.
-
How To Buy Cryo-Cell International, Inc. Stock Online?
In order to purchase Cryo-Cell International, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CCEL Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CCEL
Sector
P/E ratio
498.00x
23.41x
PEG ratio
--
-0.01x
P/B ratio
--
1.78x
Price / LTM sales
0.86x
1.56x
Growth Metrics
CCEL
Sector
Revenue growth
-2.99%
3.51%
Earnings growth
-27.89%
9.95%
Revenue (5-year growth)
0.11%
6.45%
Earnings forecast
-$0.09
-$0.19
Profitability
CCEL
Sector
Profitability FY 2024
$23.6M
$2.6M
Return on invested capital
-20.01%
-33.25%
Return on assets
-0.74%
-29.68%
Return on equity
--
-38.71%
Earnings Date
Last Earnings Date
Feb
22
Next Earnings Date
Feb
22
Estimated Next Earnings Date
May
24
Balance Sheet
CCEL
Sector
Total cash
$3.2M
$25M
Short term investments
$2.9M
$24M
Total assets
$64.7M
$71.9M
Long term debt
$9M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
